Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Research
    • Structural Heart Disease
    • TAVR
    • Therapies
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe

Search form

Home
News You Need to Know Today
News Alert: FDA approves first anti-inflammatory drug for treating cardiovascular disease
Tuesday, June 20, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

READ MORE >
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

Share on Twitter Share on Facebook Share on Linkedin
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.
The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Economics & Policy | April 2020
Pandemic watch: The biggest COVID-19 news in cardiology, all in one place
Week in Review: High doses of chloroquine ‘might be toxic’ for coronavirus patients | The pandemic's impact on cardiology
Electrophysiology & Arrhythmia | April 2020
Pandemic watch: The biggest COVID-19 news in cardiology, all in one place
Week in Review: Using hydroxychloroquine, azithromycin to treat COVID-19 | Are patients afraid to seek medical attention?
The many challenges hospitals face during COVID-19 pandemic | Are patients afraid to seek medical attention?

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …240
    • Page 241
    • Page 242
    • Page 243
    • Current page 244
    • Page 245
    • Page 246
    • Page 247
    • Page 248 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Sitemap
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • AI in Healthcare
  • Cardiovascular Business
  • HealthExec
  • Health Imaging
  • Radiology Business
 
© 2024 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup